Southeastern University FireScholars Selected Honors eses 4-2015 e erapeutic Role of Turmeric in Treatment and Prevention of Alzheimer’s Disease Rylan M. McQuade Southeastern University - Lakeland Follow this and additional works at: hp://firescholars.seu.edu/honors Part of the Alternative and Complementary Medicine Commons , Nervous System Diseases Commons , Neurology Commons , and the Neurosciences Commons is esis is brought to you for free and open access by FireScholars. It has been accepted for inclusion in Selected Honors eses by an authorized administrator of FireScholars. For more information, please contact fi[email protected]. Recommended Citation McQuade, Rylan M., "e erapeutic Role of Turmeric in Treatment and Prevention of Alzheimer’s Disease" (2015). Selected Honors eses. Paper 23.
62
Embed
The Therapeutic Role of Turmeric in Treatment and ...
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Southeastern UniversityFireScholars
Selected Honors Theses
4-2015
The Therapeutic Role of Turmeric in Treatmentand Prevention of Alzheimer’s DiseaseRylan M. McQuadeSoutheastern University - Lakeland
Follow this and additional works at: http://firescholars.seu.edu/honors
Part of the Alternative and Complementary Medicine Commons, Nervous System DiseasesCommons, Neurology Commons, and the Neurosciences Commons
This Thesis is brought to you for free and open access by FireScholars. It has been accepted for inclusion in Selected Honors Theses by an authorizedadministrator of FireScholars. For more information, please contact [email protected].
Recommended CitationMcQuade, Rylan M., "The Therapeutic Role of Turmeric in Treatment and Prevention of Alzheimer’s Disease" (2015). Selected HonorsTheses. Paper 23.
activity and also provides increased neural protection
against exogenous metals, tau proteins, and extracellular
McQuade 42
shows the multiple methods by which curcumin modulates molecular factors
McQuade 43
involved in AD ontology and progression. Turmeric offers a safer and more effective
treatment than NSAIDS, cholinesterase inhibitors, or anti-inflammatory medications.108
Future studies must investigate the role of turmeric paired with other therapeutic
compounds, such as liquiritin, CP, and shankhpushpi. To date, several studies have
underscored the importance of CP and liquiritin, but none have ever investigated
potential synergistic effects when used in tandem.119
Prospects for Future Studies
Study Purpose: The main purpose of this study is to determine the efficacy of turmeric
for the treatment of AD. Hence, the aims of this prospective study are two-fold. First, this
study will determine turmeric’s impact on amyloid-β plaque deposition in transgenic AD
models in very early stages of the disease. Secondly, it will determine the effect of
turmeric on improvement of spatial learning, coordination, and balance in stage 2
Alzheimer mice.
Experimental Design: This study will be preformed across a span of six months using a
total of 100 test subjects (Mus musculus) divided into four groups. Results from each
group will be collected on a daily basis. This study will be performed during a period
of six months using a total of 100 test subjects (Mus musculus) divided into four
groups. Results from each group will be collected on a daily basis. Before beginning
the study, all mice (AD and healthy) will be pre-screened to measure blood pressure,
coordination and balance, etc. Conduct brain scans of normal mice and Stage 1
transgenic Alzheimer mice. Scans measuring brain activity between the two groups
will be compared and evaluated. Four groups will be created (each containing 25
subjects)
1). Group A1 will consist of healthy mice that consume standard lab-grade rodent
feed.
McQuade 44
2). Group A2 will consist of healthy mice that consume a mixture of standard lab-
grade rodent feed with 5 mg/kg of freshly ground turmeric added. Two grams of
turmeric will be added to every liter of water.
3). Group B1 will contain Alzheimer’s mice and will only consume lab-grade rodent
feed.
4). Group B2 will contain Alzheimer’s mice, but will consume lab-grade feed with 5
mg/kg of turmeric added to food and 2 grams of freshly ground turmeric added per
liter of drinking water. Each mouse will receive its own separate cage with
individual food and water. Amount of food/water consumed will be measured and
appropriated for each mouse. All other elements besides food will be kept as
constant as possible. SMase activity will be closely monitored (both acidic and basic
forms). Plasma levels of SMase and a fluorescent assays will be used to collect
enzyme activity. COX-2 activity will be measured as well as reactive oxygen species
(ROS). Enzyme activity will be determined using Michaelis-Menten kinetics and
evaluated appropriately. Enzymes in blood serum and CSF will also be collected and
measured. PLA2 and ceramide activities will be evaluated for each of the four
groups. Data will be statistically evaluated using appropriate parameters.
Mice will be tested periodically every 2 weeks and be subject to a variety of
balance/strength/coordination tests. Rotarod test Morris water navigation task, the
grip test meter test, maze tests, and a balance beam will all be used. All results will
be evaluated using appropriate statistical methods. Extensive collection of data will
be conducted throughout the course of the experiment. After a period of six months,
all mice will be sacrificed and overall brain appearance will be evaluated by a team
of researchers. Brains will be tested for plaques, lesions, demyelination, tissue
shrinkage, or any other pathological or abnormal signs.
Necropsy: After 60 days, all subjects will be terminated via CO2 asphyxiation and a
necropsy will be preformed to determine the degree to which amyloid-beta plaques have
accumulated in the brain.
McQuade 45
Hypothesis: Mice consuming a turmeric-containing diet will demonstrate lowered
susceptibility to development of AD. Also, AD mice on the turmeric diet will show fewer
motor/coordination abnormalities than the AD group that did not receive turmeric.
Prevention of Unnecessary Pain: If mice display intense pain or suffering, they will be
terminated humanely using CO2 asphyxiation.
Problems/Obstacles: The most probable foreseen obstacle in this study is whether
positive results can be pinpointed to turmeric’s medicinal activity or due to some other
unforeseen factor. Although a quantitative evaluation of results will be conducted, this
study cannot rule out some other confounding factor that influenced turmeric’s activity.
Also, it is unknown whether some component of the lab-grade rat feed exerts a
beneficial/negative effect upon turmeric’s activity, both through absorption in the
bloodstream and activity in the nervous system. Although environmental factors can be
carefully manipulated, there is no guarantee that all conditions for every group will be
equivalent.
Significance of Study: Many researchers suspect that turmeric possesses incredible
potential as a medicinal chemical compound. This must be determined experimentally
before turmeric is implemented in a hospital or clinical setting. The future of turmeric as
a healthful compound is dependent upon this study and other related investigations.
Future Directions: Avenues of future research are largely contingent upon experimental
results. If the turmeric-fed mice exhibit retardation of AD progression, future research
should determine turmeric’s optimal dosage for Alzheimer’s patients. Although
investigating this issue to some extent, this current study will not elucidate all details of
effective drug regimen. Also, future studies must determine if turmeric is best taken alone
or in combination with another compound. In particular, CP and liquiritin are two
compounds are special interest Methods will be suggested as to certain novel compounds
that can be screened for medicinal efficiency. Many current studies complain that
turmeric is poorly absorbed because of its relatively poor solubility in water.
McQuade 46
Discussion
As multiple studies demonstrate, NSAIDs can mediate immune response, but they
do not effectively reduce Aβ plaques.10
Although well-intentioned, current drug designs
suffer from a fundamental flaw in their production-- they are derived largely from
empirical methods and do not usually begin with a presuppositional framework in mind.
This directly leads to the treatment of specific disease symptoms (COX-2 reduction,
thromboxane inhibition, etc.) without targeting the basic cause of the disease. Since these
therapies are limited in scope, they also demonstrate numerous secondary effects, some
of which are deadly. Although offering great potential, memantine suffers from short-
term activity as neural receptors quickly accommodate. Likewise, lithium fails to offer
consistently reliable results (and also demonstrates mixed experimental results). Lithium
has also garnished concern over its potentially toxic effect to body organs.95
Therefore,
neither lithium nor memantine can be employed for patient care or for any kind of long-
term treatment. In contrast to pharmaceutical compounds, turmeric offers a wide range of
healthful effects. Despite some studies that demonstrate poor solubility, research has
determined that fortification with LAB significantly increases turmeric’s bioavailability.
This finding suggests that turmeric used for AD therapy should be intentionally grown in
the presence of LAB and should be consumed in the freshest form possible. Further
studies must verify and add further details regarding how LAB increases curcumin’s
effectiveness.
The proposed turmeric study will elucidate further details about how turmeric
impacts AD murine models. Adjusting for any confounding factors, these findings can be
directly applied to human patients. Based on current research, it is hypothesized that
turmeric ingestion will greatly increase cognition and memory and also boost
coordination and muscle control. Future studies will investigate dosage considerations
and whether turmeric is best used in combination with other compounds or taken by
itself. Other transgenic model organisms will be tested to determine if turmeric’s effects
are confined to one species or can impact many different species. It is presumed that the
latter scenario will be proven correct and that each organism will utilize similar cascades
and molecular mechanisms in metabolism of turmeric.
McQuade 47
Conclusion
Despite the valiant efforts of researchers and physicians, AD still remains an
incurable and deadly disease. Impacting millions around the world each year, it is
especially prevalent in America and Europe and targets the elderly demographic.81
AD is
a complex, multifactorial disease that is typified by external Aβ plaques and internal
NFTs (due to faulty secretase cleavage of APP and excessive tau phosphorylation
respectively).20
Historically, the Homo sapiens genome has always displayed a potential
for AD development; widespread Alzheimer’s, however, is a relatively recent
phenomenon due to longer lifespans and harmful environmental factors.13
It is
hypothesized that upregulation of inflammatory cascades (driven by AA and ceramide
production) are the major stimulant in driving disease pathology.74
A complex interplay
of diet, gene expression, and organism variability is implicated in this process. It is
believed that this internal inflammation provides the motive force behind SP and NFT
accumulation. By means of a vicious cycle, even the body’s own immune response
stimulates disease conditions through microglial activation.85
Likewise, the “cytokine
storm” produced by AA and ceramide pathways only increase inflammation, caspase
activity, and cell necrosis. Multiple drug regimens have been developed for treating AD,
but so far are only mildly effective (or even detrimental in many cases). Although
demonstrating some potential, COX-2 and cholinesterase inhibitors are not yet suitable
for patient use and their efficacy in treating AD is doubtful.87
Even NSAIDs (perhaps the
most effective of AD therapeutics) and memantine are extremely time-dependent, and
their usefulness rapidly declines with each use.10,88
In the absence of a useful AD
therapeutic, researchers are desperately searching for novel compounds that produce
clinical results. As multiple studies show, the burden of evidence weighs heavily on
turmeric, warranting the need for further clinical and experimental investigations.3,105,106
It is hoped that turmeric will turn the tide of disease progression and restore cognitive,
learning, and STM functions.16
Additionally, a turmeric-based drug regimen will inhibit
neuroinflammation by retroactively preventing exorbitant eicosanoid expression by
deactivation of PGH2 synthase (COX-2).114
Although most neural damage is irreversible,
curcumin will demolish existent Aβ plaques, unravel NFTs, and prevent apoptotic
McQuade 48
activity.118
It is tantamount that turmeric therapies be administered in the earliest stages
of the disease since this promises the greatest chance of a full recovery. These
conclusions will be investigated further in the “Proposed Study” section, which will test
how turmeric affects motor skills, coordination, and balance of transgenic Alzheimer
mice. Because of its widespread effects in targeting SPs and NFTs, impacting AA and
sphingomyelinase cascades, and halting ROS, turmeric warrants incorporation into
Western medicinal practice. It is hoped that turmeric may be used in tandem with another
medicinally useful compounds (natural or synthetic) to ebb the tide of AD.108
Of all
potential therapies, turmeric will halt the Alzheimer epidemic and its ravaging grip on
Western society.
McQuade 49
References
1. De Strooper B, Woodgett J. Alzheimer’s disease: Mental plaque removal. Nature. 2003;423(6938):392.
2. Trazzi S, Fuchs C, De Franceschi M, Mitrugno VM, Bartesaghi R, Ciani E. APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis. 2014;67:24-36. doi:10.1016/j.nbd.2014.03.003.
3. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids. 1995;52(4):223-227.
4. Bandyopadhyay S, Rogers JT. Alzheimer’s disease therapeutics targeted to the control of amyloid precursor protein translation: Maintenance of brain iron homeostasis. Biochem Pharmacol. 2014;88(4):486-494. doi:10.1016/j.bcp.2014.01.032.
5. Davidson JE, Lockhart A, Amos L, et al. Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer’s disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. Alzheimers Res Ther. 2012;4(6):1-7. doi:10.1186/alzrt154.
6. Beecham GW, Hamilton K, Naj AC, et al. Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer’s Disease and Related Dementias. PLoS Genet. 2014;10(9):1-15. doi:10.1371/journal.pgen.1004606.
7. Pietri M, Dakowski C, Hannaoui S, et al. PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer’s diseases. Nat Med. 2013;19(9):1124-1131. doi:10.1038/nm.3302.
8. Henry A, Li Q-X, Galatis D, et al. Inhibition of platelet activation by the Alzheimer’s disease amyloid precursor protein. Br J Haematol. 1998;103(2):402-415.
9. Lambert MA, Bickel H, Prince M, et al. Estimating the burden of early onset dementia; systematic review of disease prevalence. Eur J Neurol. 2014;21(4):563-569. doi:10.1111/ene.12325.
10. Trepanier CH, Milgram NW. Neuroinflammation in Alzheimer’s Disease: Are NSAIDs and Selective COX-2 Inhibitors the Next Line of Therapy? J Alzheimers
Dis. 2010;21(4):1089-1099.
McQuade 50
11. Igarashi M, Kaizong Ma, Fei Gao, Hyung-Wook Kim, Rapoport SI, Rao JS. Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex. J Alzheimers Dis. 2011;24(3):507-517. doi:10.3233/JAD-2011-101608.
12. Cheng JS, Craft R, Yu G-Q, et al. Tau Reduction Diminishes Spatial Learning and Memory Deficits after Mild Repetitive Traumatic Brain Injury in Mice. PLoS
13. Keleshian VL, Modi HR, Rapoport SI, Rao JS. Aging is associated with altered inflammatory, arachidonic acid cascade, and synaptic markers, influenced by epigenetic modifications, in the human frontal cortex. J Neurochem. 2013;125(1):63-73. doi:10.1111/jnc.12153.
14. Ferreira LK, Tamashiro-Duran JH, Squarzoni P, et al. The link between cardiovascular risk, Alzheimer’s disease, and mild cognitive impairment: support from recent functional neuroimaging studies. Rev Bras Psiquiatr. 2014;36(4):344-357. doi:10.1590/1516-4446-2013-1275.
15. Engstrom EJ. Researching Dementia in Imperial Germany: Alois Alzheimer and the Economies of Psychiatric Practice. Cult Med Psychiatry. 2007;31(3):405-413. doi:10.1007/s11013-007-9060-4.
16. Caza N, Belleville S. Reduced short-term memory capacity in Alzheimer’s disease: The role of phonological, lexical, and semantic processing. Memory. 2008;16(4):341-350. doi:10.1080/09658210701881758.
17. Gnjidic D, Hilmer SN, Hartikainen S, et al. Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer’s Disease: A National Population Cohort Study. PLoS ONE. 2014;9(1):1-8. doi:10.1371/journal.pone.0083224.
18. Panchal M, Loeper J, Cossec J-C, et al. Enrichment of cholesterol in microdissected Alzheimer’s disease senile plaques as assessed by mass spectrometry. J Lipid Res. 2010;51(3):598-605. doi:10.1194/jlr.M001859.
19. Zilka N, Kazmerova Z, Jadhav S, et al. Who fans the flames of Alzheimer’s disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation. 2012;9:47. doi:10.1186/1742-2094-9-47.
20. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337-351. doi:10.1016/j.neuron.2007.01.010.
McQuade 51
21. Mirza Z, Pillai VG, Kamal MA. Protein Interactions Between the C-terminus of Aβ-Peptide and Phospholipase A2 - A Structure Biology Based Approach to Identify Novel Alzheimer Therapeutics. CNS Neurol Disord Drug Targets. 2014.
22. Grimm MOW, Haupenthal VJ, Rothhaar TL, et al. Effect of Different Phospholipids on α-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer’s Disease. Int J Mol Sci. 2013;14(3):5879-S13. doi:10.3390/ijms14035879.
23. Fragkouli A, Tzinia AK, Charalampopoulos I, Gravanis A, Tsilibary EC. Matrix Metalloproteinase-9 Participates in NGF-Induced α-Secretase Cleavage of Amyloid-β Protein Precursor in PC12 Cells. J Alzheimers Dis. 2011;24(4):705-719. doi:10.3233/JAD-2011-101893.
24. Karr JW, Szalai VA. Cu(II) Binding to Monomeric, Oligomeric, and Fibrillar Forms of the Alzheimer’s Disease Amyloid-β Peptide. Biochemistry (Mosc). 2008;47(17):5006-5016.
25. Joshi YB, Di Meco A, Praticó D. Modulation of Amyloid-β Production by Leukotriene B4 via the γ-Secretase Pathway. J Alzheimers Dis. 2014;38(3):503-506. doi:10.3233/JAD-131223.
26. Li JJ, Dolios G, Wang R, Liao F-F. Soluble Beta-Amyloid Peptides, but Not Insoluble Fibrils, Have Specific Effect on Neuronal MicroRNA Expression. PLoS
27. Malaplate-Armand C, Florent-Béchard S, Youssef I, et al. Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis. 2006;23(1):178-189. doi:10.1016/j.nbd.2006.02.010.
28. Shelat PB, Chalimoniuk M, Wang J-H, et al. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem. 2008;106(1):45-55. doi:10.1111/j.1471-4159.2008.05347.x.
29. Yi Li, Bohm C, Dodd R, et al. Structural biology of presenilin 1 complexes. Mol
30. Brendel M, Jaworska A, Grießinger E, et al. Cross-Sectional Comparison of Small Animal [18F]-Florbetaben Amyloid-PET between Transgenic AD Mouse Models. PLoS ONE. 2015;10(2):1-21. doi:10.1371/journal.pone.0116678.
31. Chang Liu, Jianwei Tang. Expression levels of tumor necrosis factor-α and the corresponding receptors are correlated with trauma severity. Oncol Lett. 2014;8(6):2747-2751. doi:10.3892/ol.2014.2575.
McQuade 52
32. Fatima A, Hj. Abdul AB, Abdullah R, Karjiban RA, Lee VS. Binding Mode Analysis of Zerumbone to Key Signal Proteins in the Tumor Necrosis Factor Pathway. Int
33. Rosenthal JA, Huang C-J, Doody AM, et al. Mechanistic Insight into the TH1-Biased Immune Response to Recombinant Subunit Vaccines Delivered by Probiotic Bacteria-Derived Outer Membrane Vesicles. PLoS ONE. 2014;9(11):1-24. doi:10.1371/journal.pone.0112802.
34. Dolcino M, Patuzzo G, Barbieri A, et al. Gene Expression Profiling in Peripheral Blood Mononuclear Cells of Patients with Common Variable Immunodeficiency: Modulation of Adaptive Immune Response following Intravenous Immunoglobulin Therapy. PLoS ONE. 2014;9(5):1-9. doi:10.1371/journal.pone.0097571.
35. Lundin JI, Checkoway H. Endotoxin and Cancer. Environ Health Perspect. 2009;117(9):1344-1350. doi:10.1289/ehp.0800439.
36. Nguyen A, Louisa Ho, Yonghong Wan. Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer. Front Oncol. 2014;4:1-10. doi:10.3389/fonc.2014.00145.
37. Hsien-San Hou, Hsieh-Fu Tsai, Hsien-Tai Chiu, Ji-Yen Cheng. Simultaneous chemical and electrical stimulation on lung cancer cells using a multichannel-dual-electric-field chip. Biomicrofluidics. 2014;8(5):1-15. doi:10.1063/1.4896296.
38. An Zhou, Hongfei Wu, Jian Pan, et al. Synthesis and Evaluation of Paeonol Derivatives as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease. Molecules. 2015;20(1):1304-1318. doi:10.3390/molecules20011304.
39. Grösgen S, Grimm MOW, Frieß P, Hartmann T. Role of amyloid beta in lipid homeostasis. BBA - Mol Cell Biol Lipids. 2010;1801(8):966-974. doi:10.1016/j.bbalip.2010.05.002.
40. Straub BK, Gyoengyoesi B, Koenig M, et al. Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation. Histopathology. 2013;62(4):617-631. doi:10.1111/his.12038.
41. Atsuhiko Ichimura, Sae Hasegawa, Mayu Kasubuchi, Ikuo Kimura, Hudson B, Cho TY. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol. 2014;5:1-6. doi:10.3389/fphar.2014.00236.
42. Tajima Y, Ishikawa M, Maekawa K, et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor
McQuade 53
protein/tau for Alzheimer’s disease. Lipids Health Dis. 2013;12(1):1-14. doi:10.1186/1476-511X-12-68.
43. Mirza Z, Pillai VG, Zhong W-Z. Structure of N-terminal sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser of Aβ-peptide with phospholipase A2 from venom of Andaman Cobra sub-species Naja naja sagittifera at 2.0 Å resolution. Int J Mol
44. Quach ND, Arnold RD, Cummings BS. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol. 2014;90(4):338-348. doi:10.1016/j.bcp.2014.05.022.
45. Dennis EA, Cao J, Hsu Y-H, Magrioti V, Kokotos G. Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention. Chem Rev. 2011;111(10):6130-6185. doi:10.1021/cr200085w.
46. Okumura K, Ohno A, Nishida M, Hayashi K, Ikeda K, Inoue S. Mapping the Region of the α-Type Phospholipase A₂ Inhibitor Responsible for Its Inhibitory Activity. J Biol Chem. 2005;280(45):37651-37659. doi:10.1074/jbc.M507250200.
47. Haowei Song, Wohltmann M, Min Tan, Shunzhong Bao, Ladenson JH, Turk J. Group VIA PLA2 (iPLA2β) Is Activated Upstream of p38 Mitogen-activated Protein Kinase (MAPK) in Pancreatic Islet β-Cell Signaling. J Biol Chem. 2012;287(8):5528-5541. doi:10.1074/jbc.M111.285114.
48. Moscardó A, Vallés J, Piñón M, Aznar J, Martínez-Sales V, Santos M-T. Regulation of cytosolic PlA 2 activity by PP1/PP2A serine/threonine phosphatases in human platelets. Platelets. 2006;17(6):405-415. doi:10.1080/09537100600757869.
49. Ryan VH, Primiani CT, Rao JS, Ahn K, Rapoport SI, Blanchard H. Coordination of Gene Expression of Arachidonic and Docosahexaenoic Acid Cascade Enzymes during Human Brain Development and Aging. PLoS ONE. 2014;9(6):1-12. doi:10.1371/journal.pone.0100858.
50. Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42(3):174-181. doi:10.1111/j.1469-8749.2000.tb00066.x.
51. Stawarska A, Białek A, Stanimirova I, Stawarski T, Tokarz A. The Effect of Conjugated Linoleic Acids (CLA) Supplementation on the Activity of Enzymes Participating in the Formation of Arachidonic Acid in Liver Microsomes of Rats—Probable Mechanism of CLA Anticancer Activity. Nutr Cancer. 2015;67(1):145-155. doi:10.1080/01635581.2015.967875.
McQuade 54
52. Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA. Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer’s disease pathology. Prog Lipid Res. 2011;50(4):313-330. doi:10.1016/j.plipres.2011.06.001.
53. Yin H, Zhou Y, Zhu M, et al. Role of mitochondria in programmed cell death mediated by arachidonic acid-derived eicosanoids. Mitochondrion. 2013;13(3):209-224. doi:10.1016/j.mito.2012.10.003.
54. Sarkar P, Narayanan J, Harder D r. Differential effect of amyloid beta on the cytochrome P450 epoxygenase activity in rat brain. Neuroscience. 2011;194:241-249. doi:10.1016/j.neuroscience.2011.07.058.
55. Tang S-S, Hong H, Chen L, et al. Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo. Neurobiol Aging. 2014;35(3):590-599. doi:10.1016/j.neurobiolaging.2013.09.036.
56. Yang G, Haczku A, Chen H. Transgenic smooth muscle expression of the human CysLT1, receptor induces enhanced responsiveness of murine airways to leukotriene D4. Am J Physiol. 2004;286(5):L992-L1001.
57. Samuelsson B. Arachidonic acid metabolism: role in inflammation. Z Für
Rheumatol. 1991;50 Suppl 1:3-6.
58. Hayashi L, Sheth M, Young A, Kruger M, Wayman GA, Coffin AB. The effect of the aquatic contaminants bisphenol-A and PCB-95 on the zebrafish lateral line. NeuroToxicology. 2015;46:125-136. doi:10.1016/j.neuro.2014.12.010.
59. Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. GSK-3a regulates production of Alzheimer’s disease amyloid-b peptides. Nature. 2003;423(6938):435.
60. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta. 1992;1114(2-3):147-162.
61. Teixeira Mendes C, Borges Mury F, De Sá Moreira E, et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry
62. Janssen CIF, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: The influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res. 2014;53:1-17. doi:10.1016/j.plipres.2013.10.002.
63. Shimizu T, Wolfe LS. Arachidonic Acid Cascade and Signal Transduction. J Neurochem. 1990;55(1):1-15. doi:10.1111/j.1471-4159.1990.tb08813.x.
McQuade 55
64. Beaulieu E, Ioffe J, Watson SN, Hermann PM, Wildering WC. Oxidative-stress induced increase in circulating fatty acids does not contribute to phospholipase A2-dependent appetitive long-term memory failure in the pond snail Lymnaea stagnalis. BMC Neurosci. 2014;15(1):2-28. doi:10.1186/1471-2202-15-56.
65. Upadhyay P, Panjwani D, Yadav AK. Neuropathology staging and treatment strategies of Alzheimer’s disease: An update. Int J Nutr Pharmacol Neurol Dis. 2014;4(1):28-42. doi:10.4103/2231-0738.124612.
66. Cheng K, Delghingaro-Augusto V, Nolan CJ, et al. High Passage MIN6 Cells Have Impaired Insulin Secretion with Impaired Glucose and Lipid Oxidation. PLoS
ONE. 2012;7(7). doi:10.1371/journal.pone.0040868.
67. DaRocha-Souto B, Coma M, Pérez-Nievas B g., et al. Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer’s disease. Neurobiol Dis. 2012;45(1):425-437. doi:10.1016/j.nbd.2011.09.002.
68. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem. 2006;96(4):1005-1015. doi:10.1111/j.1471-4159.2005.03637.x.
69. Jelenik T, Roden M. Mitochondrial Plasticity in Obesity and Diabetes Mellitus. Antioxid Redox Signal. 2013;19(3):258-268. doi:10.1089/ars.2012.4910.
70. Teng L, Meng Q, Lu J, et al. Liquiritin modulates ERK‑ and AKT/GSK‑3β‑dependent pathways to protect against glutamate‑induced cell damage in differentiated PC12 cells. Mol Med Rep. 2014;10(2):818-824. doi:10.3892/mmr.2014.2289.
71. Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26(12):2694-2701. doi:10.1016/j.cellsig.2014.08.019.
72. Rahmati M, Gharakhanlou R, Movahedin M, et al. Treadmill Training Modifies KIF5B Moter Protein in the STZ-induced Diabetic Rat Spinal Cord and Sciatic Nerve. Arch Iran Med AIM. 2015;18(2):94-101.
73. Panchal M, Gaudin M, Lazar AN, et al. Ceramides and sphingomyelinases in senile plaques. Neurobiol Dis. 2014;65:193-201. doi:10.1016/j.nbd.2014.01.010.
74. LiZe Gu, BaoSheng Huang, Wei Shen, et al. Early activation of nSMase2/ceramide pathway in astrocytes is involved in ischemia-associated
McQuade 56
neuronal damage via inflammation in rat hippocampi. J Neuroinflammation. 2013;10(1):1-16. doi:10.1186/1742-2094-10-109.
75. Chatterjee S. Neutral sphingomyelinase action stimulates signal transduction of tumor necrosis factor-alpha in the synthesis of cholesteryl esters in human fibroblasts. J Biol Chem. 1994;269(2):879-882.
76. Haughey NJ, Bandaru VVR, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. BBA - Mol
77. Grimm MOW., Grimm HS., Pätzold AJ., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat Cell Biol. 2005;7(11):1118-1123. doi:10.1038/ncb1313.
78. Tabner BJ, Mayes J, Allsop D. Hypothesis: Soluble Aβ Oligomers in Association with Redox-Active Metal Ions Are the Optimal Generators of Reactive Oxygen Species in Alzheimer’s Disease. Int J Alzheimers Dis. 2011;2011:1-6. doi:10.4061/2011/546380.
79. Perez J l., Carrero I, Gonzalo P, et al. Soluble oligomeric forms of beta-amyloid (Aβ) peptide stimulate Aβ production via astrogliosis in the rat brain. Exp
80. Kornhuber J, Muehlbacher M, Trapp S, et al. Identification of Novel Functional Inhibitors of Acid Sphingomyelinase. PLoS ONE. 2011;6(8):1-13. doi:10.1371/journal.pone.0023852.
81. Yagami T. Cerebral Arachidonate Cascade in Dementia: Alzheimer’s Disease and Vascular Dementia. Curr Neuropharmacol. 2006;4(1):87-100. doi:10.2174/157015906775203011.
82. Frisardi V, Panza F, Farooqui AA. Late-life depression and Alzheimer’s disease: The glutamatergic system inside of this mirror relationship. Brain Res Rev. 2011;67(1/2):344-355. doi:10.1016/j.brainresrev.2011.04.003.
83. Choi S-H, Aid S, Kim H-W, Jackson SH, Bosetti F. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem. 2012;120(2):292-301. doi:10.1111/j.1471-4159.2011.07572.x.
84. Aïd S, Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie. 2011;93(1):46-51. doi:10.1016/j.biochi.2010.09.009.
McQuade 57
85. Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A. Accelerated microglial pathology is associated with Aβ plaques in mouse models of Alzheimer’s disease. Aging Cell. 2014;13(4):584-595. doi:10.1111/acel.12210.
86. Lee YS, Lee SJ, Seo KW, Bae JU, Park SY, Kim CD. Homocysteine induces COX-2 expression in macrophages through ROS generated by NMDA receptor-calcium signaling pathways. Free Radic Res. 2013;47(5):422-431. doi:10.3109/10715762.2013.784965.
87. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Rev. 2005;48(2):352-359. doi:10.1016/j.brainresrev.2004.12.024.
88. Parsons C, Danysz W, Dekundy A, Pulte I. Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease. Neurotox Res. 2013;24(3):358-369. doi:10.1007/s12640-013-9398-z.
89. Lee SJ, Ritchie CS, Yaffe K, Stijacic Cenzer I, Barnes DE. A Clinical Index to Predict Progression from Mild Cognitive Impairment to Dementia Due to Alzheimer’s Disease. PLoS ONE. 2014;9(12):1-15. doi:10.1371/journal.pone.0113535.
90. Wang J, Tan L, Wang H-F, et al. Anti-Inflammatory Drugs and Risk of Alzheimer’s Disease: An Updated Systematic Review and Meta-Analysis. J Alzheimers Dis. 2015;44(2):385-396. doi:10.3233/JAD-141506.
91. Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF. Does Lithium Prevent Alzheimer’s Disease? Drugs Aging. 2012;29(5):335-342. doi:10.2165/11599180-000000000-00000.
92. Lawrence D. Lithium as a potential Alzheimer’s treatment? Lancet. 2003;361(9371):1796.
93. Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti F. Lithium Improves Hippocampal Neurogenesis, Neuropathology and Cognitive Functions in APP Mutant Mice. PLoS ONE. 2010;5(12):1-19. doi:10.1371/journal.pone.0014382.
94. Verzola D, Ratto E, Villaggio B, et al. Uric Acid Promotes Apoptosis in Human Proximal Tubule Cells by Oxidative Stress and the Activation of NADPH Oxidase NOX 4. PLoS ONE. 2014;9(12):1-19. doi:10.1371/journal.pone.0115210.
95. Nakashima H, Ishihara T, Suguimoto P, et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol (Berl). 2005;110(6):547-556. doi:10.1007/s00401-005-1087-4.
McQuade 58
96. Xie C, Zhou K, Wang X, Blomgren K, Zhu C. Therapeutic Benefits of Delayed Lithium Administration in the Neonatal Rat after Cerebral Hypoxia-Ischemia. PLoS ONE. 2014;9(9):1-6. doi:10.1371/journal.pone.0107192.
97. Marmol F. Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog
98. Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease. J Neurochem. 2012;120:22-33. doi:10.1111/j.1471-4159.2011.07507.x.
99. Pomponi MFL, Gambassi G, Pomponi M, Masullo C. Alzheimer’s Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. Aging Dis. 2010;1(1):37-59.
100. Xu X, Li Z, Yang Z, Zhang T. Decrease of synaptic plasticity associated with alteration of information flow in a rat model of vascular dementia. Neuroscience. 2012;206:136-143. doi:10.1016/j.neuroscience.2011.12.050.
101. Weng P-H, Chen J-H, Chen T-F, et al. CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer’s Disease. PLoS ONE. 2013;8(12):1-8. doi:10.1371/journal.pone.0084059.
102. Altena R, Fehrmann RSN, Boer H, de Vries EGE, Meijer C, Gietema JA. Growth Differentiation Factor 15 (GDF-15) Plasma Levels Increase during Bleomycin- and Cisplatin-Based Treatment of Testicular Cancer Patients and Relate to Endothelial Damage. PLoS ONE. 2015;10(1):1-15. doi:10.1371/journal.pone.0115372.
103. Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutr J. 2014;13(1):1-18. doi:10.1186/1475-2891-13-11.
104. Belkov M, Polozov G, Skornyakov I, Tolstorozhev G, Shadyro O. Infrared spectra and pharmacological activity of hindered phenols. J Appl Spectrosc. 2011;78(3):400-405. doi:10.1007/s10812-011-9472-3.
105. Tayyem RF, Heath DD, Al-Delaimy WK, Rock CL. Curcumin content of turmeric and curry powders. Nutr Cancer. 2006;55(2):126-131. doi:10.1207/s15327914nc5502_2.
106. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol. 2008;11(1):13-19. doi:10.4103/0972-2327.40220.
McQuade 59
107. Chandra AK, Parveen S, Das S, Zeegers-Huyskens T. Blue shifts of the C&bond;H stretching vibrations in hydrogen-bonded and protonated trimethylamine. Effect of hyperconjugation on bond properties. J Comput Chem. 2008;29(9):1490-1496. doi:10.1002/jcc.20910.
108. Pianpumepong P, Anal AK, Doungchawee G, Noomhorm A. Study on enhanced absorption of phenolic compounds of Lactobacillus-fermented turmeric ( Curcuma longa Linn.) beverages in rats. Int J Food Sci Technol. 2012;47(11):2380-2387. doi:10.1111/j.1365-2621.2012.03113.x.
109. Potter PE. Curcumin: a natural substance with potential efficacy in Alzheimer’s disease. J Exp Pharmacol. 2013;5:23-31. doi:10.2147/JEP.S26803.
110. Welak SR, Rentea RM, Teng R-J, et al. Intestinal NADPH Oxidase 2 Activity Increases in a Neonatal Rat Model of Necrotizing Enterocolitis. PLoS ONE. 2014;9(12):1-15. doi:10.1371/journal.pone.0115317.
111. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis. 2004;25(9):1671-1679. doi:10.1093/carcin/bgh165.
112. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol
113. Meng J, Li Y, Camarillo C, et al. The Anti-Tumor Histone Deacetylase Inhibitor SAHA and the Natural Flavonoid Curcumin Exhibit Synergistic Neuroprotection against Amyloid-Beta Toxicity. PLoS ONE. 2014;9(1):1-11. doi:10.1371/journal.pone.0085570.
114. Ka-Heng Lee, Abas F, Mohamed Alitheen NB, Shaari K, Lajis NH, Ahmad S. A Curcumin Derivative, 2,6-Bis(2,5-dimethoxybenzylidene)-cyclohexanone (BDMC33) Attenuates Prostaglandin E2 Synthesis via Selective Suppression of Cyclooxygenase-2 in IFN-γ/LPS-Stimulated Macrophages. Molecules. 2011;16(11):9728-9738. doi:10.3390/molecules16119728.
115. Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutr J. 2014;13(1):1-18. doi:10.1186/1475-2891-13-11.
116. Ahmad W, Kumolosasi E, Jantan I, Bukhari SNA, Jasamai M. Effects of Novel Diarylpentanoid Analogues of Curcumin on Secretory Phospholipase A2, Cyclooxygenases, Lipo-oxygenase, and Microsomal Prostaglandin E Synthase-1. Chem Biol Drug Des. 2014;83(6):670-681. doi:10.1111/cbdd.12280.
McQuade 60
117. Pecchi E, Dallaporta M, Jean A, Thirion S, Troadec J-D. Prostaglandins and sickness behavior: Old story, new insights. Physiol Behav. 2009;97(3/4):279-292. doi:10.1016/j.physbeh.2009.02.040.
118. Abdel Shakor AB, Atia M, Ismail IA, et al. Curcumin induces apoptosis of multidrug-resistant human leukemia HL60 cells by complex pathways leading to ceramide accumulation. BBA - Mol Cell Biol Lipids. 2014;1841(12):1672-1682. doi:10.1016/j.bbalip.2014.09.006.
119. Sethiya NK, M. K. Mohan Maruga Raja, Mishra H. Antioxidant markers based TLC-DPPH differentiation on four commercialized botanical sources of Shankhpushpi (A Medhya Rasayana): A preliminary assessment. J Adv Pharm